B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy ( CAR T ) is a revolutionary treatment for fighting multiple myeloma ; however, some patients relapse post-therapy, and no further treatment options are available at this stage. A new study published in Blood analyzed 79 patients with multiple myeloma, who reported progression of disease after treatment with BCMA-directed CAR T, receiving a median of two treatment lines (a total of 237 post-CAR T salvage treatment lines were used).
The results showed that patients with multiple myeloma who relapse after BCMA-directed CAR T can be potentially treated with multiple lines of salvage therapy, having an overall survival of around 18 months. The study is the first to report the results of different therapeutic options on a large cohort of multiple myeloma patients who relapsed after anti-BCMA CAR T therapy.…
